United Therapeutics Corp. v. Liquidia Techs.
| Court | U.S. Court of Appeals — Federal Circuit |
| Writing for the Court | STOLL, CIRCUIT JUDGE. |
| Docket Number | 2022-2133 |
| Decision Date | 27 June 2024 |
| Citation | United Therapeutics Corp. v. Liquidia Techs., 2022-2133 (Fed. Cir. Jun 27, 2024) |
| Parties | UNITED THERAPEUTICS CORPORATION, Appellant v. LIQUIDIA TECHNOLOGIES, INC., Appellee KATHERINE K. VIDAL, UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE, Intervenor |
| topic | Administrative Law,Patent law,Intellectual Property |
This disposition is nonprecedential.
Appeal from the United States Patent and Trademark Office, Patent Trial and Appeal Board in No. IPR2020-00770.
WILLIAM M. JAY, Goodwin Procter LLP, Washington, DC, argued for appellant. Also represented by WILLIAM COVINGTON JACKSON JAIME SANTOS, ROHINIYURIE TASHIMA, JENNY J. ZHANG; ADAM WILLIAM BURROWBRIDGE McDermott Will &Emery, LLP, Washington, DC; DOUGLAS H. CARSTEN ARTHUR PAUL DYKHUIS, Irvine, CA; SHAUN R. SNADER, United Therapeutics Corporation, Washington, DC.
SANYA SUKDUANG, Cooley LLP, Washington, DC, argued for appellee. Also represented by JONATHAN DAVIES.
MAUREEN DONOVAN QUELER, Office of the Solicitor, United States Patent and Trademark Office, Alexandria, VA, argued for intervenor. Also represented by MARY L. KELLY, FARHEENA YASMEEN RASHEED.
Before HUGHES, STOLL, and CUNNINGHAM, Circuit Judges.
This is the case of a missing oath and purportedly missing claim limitation. United Therapeutics Corporation (UTC) appeals the Patent Trial and Appeal Board's final written decision denying UTC's motion to exclude the declaration of Dr. Jeffrey D. Winkler for failure to include an oath. UTC also appeals the Board's final written decision holding certain claims of U.S. Patent No. 9,604,901 unpatentable as obvious. We affirm the Board's denial of UTC's motion to exclude and its obviousness determination.
The '901 patent includes "an improved process to convert benzindene triol to treprostinil via salts of treprostinil and to purify treprostinil." '901 patent, Abstract. Trepros-tinil is the active ingredient in UTC's drug Remodulin®, id. at col. 1 ll. 27-32, which is used to treat pulmonary arterial hypertension, i.e., high blood pressure in the arteries that go from the heart to the lungs. According to the '901 patent, because treprostinil is "of great importance from a medicinal point of view a need exists for an efficient process to synthesize th[is] compound[] on a large scale suitable for commercial production." Id. at col. 1 l. 66-col. 2 l. 3. The '901 patent discloses "a process for the preparation of [treprostinil], or a hydrate, solvate, or pharmaceutically acceptable salt thereof." Id. at col. 8 ll. 44-46. Claim 1 is the only independent claim and is reproduced below:
1. A pharmaceutical batch consisting of treprosti-nil or a salt thereof and impurities resulting from (a) alkylating a benzindene triol, (b) hydrolyzing the product of step (a) to form a solution comprising treprostinil, (c) contacting the solution comprising treprostinil from step (b) with a base to form a salt of treprostinil, (d) isolating the salt of treprostinil, and (e) optionally reacting the salt of treprostinil with an acid to form treprostinil, and wherein the pharmaceutical batch contains at least 2.9 g of treprostinil or its salt.
'901 patent, col. 17 l. 24-col. 18 l. 2.
Liquidia's petition for inter partes review (IPR) asserts that the '901 patent is rendered obvious by Moriarty[1] in view of Phares[2]. Prior art references Moriarty and Phares describe preparation methods of treprostinil. As relevant to this appeal, Moriarty discloses synthesizing treprostinil "via the stereoselective intramolecular Pauson-Khand cyclization," which is a known way of producing treprostinil. J.A. 1471-78. And Phares teaches various compounds, including treprostinil and its derivatives. Phares states that "[a] preferred embodiment of the present invention is the diethanolamine salt of treprostinil." J.A. 1359. Phares further teaches that "the enantiomer of the commercial drug (+)-Treprostinil was synthesized using the stereoselective intramolecular Pauson Khand reaction as a key step and Mitsunobu inversion of the side-chain hydroxyl group." J.A. 1390.
Liquidia's IPR petition also included the declaration of Dr. Jeffrey D. Winkler. J.A. 91; J.A. 94; J.A. 877. The Winkler Declaration contained a signature but lacked any affirmations of truthfulness or any acknowledgement of the punishment for false statements. Following institution, UTC timely served objections to the Winkler Declaration. UTC objected to the Winkler declaration as, among other things, "lacking authentication and not self-authenticating because it lacks sufficient indicia that the exhibit is what it purports to be." J.A. 331. While Liquidia later filed a corrected Winkler declaration with an oath, the filing was late and Liquidia did not serve any timely supplemental evidence in response to UTC's objection to the Winkler declaration. See J.A. 54-57; J.A. 589; 37 C.F.R. § 42.64(b)(2).
Prior to filing its Patent Owner response, UTC deposed Dr. Winkler about his declaration. During the deposition, Dr. Winkler confirmed that he would provide truthful and accurate testimony, he had written the declaration, and that the declaration contained his signature.
Prior to the oral argument, UTC timely filed a motion to exclude the Winkler Declaration because it "purports to be a declaration, but without authentication because it lacks the statutorily-required oath or caveat for a declaration." J.A. 590 (citing 35 U.S.C. § 25 and 37 C.F.R. § 42.2). UTC asserted that statements lacking the required certifications "forgo the guarantee of truthfulness imparted by a declarant's acknowledgment of the possible consequences-fine, imprisonment, or penalty of perjury." J.A. 590 (internal quotation marks and citation omitted).
Liquidia opposed the motion to exclude and asserted that the deposition and refiled declaration rendered the "inadvertently omitted" affirmations of truthfulness harmless and otherwise cured. J.A. 602-03. UTC replied that Liquidia had never received Board authorization to file belated supplemental evidence.
At oral argument, Liquidia explained that the missing language in the Winkler Declaration was the result of a paragraph being accidentally deleted during drafting and not an intentional omission. Liquidia also emphasized the lack of prejudice to UTC, given that UTC had conducted a several-hour deposition of Dr. Winkler, and Liquidia had filed a corrected declaration with an oath. The Board explained, however, that Liquidia did not follow Board rules requiring parties to seek leave prior to submitting supplemental evidence and thus the corrected declaration would be omitted. When questioned as to whether the ability to depose Dr. Winkler resolved the issue of the missing oath, UTC's counsel reasonably conceded that he would be "hard pressed to sit here and say, you know, that we suffered a specific cognizable prejudice." J.A. 759 at 64:05-06.
After the hearing, the Board issued a final written decision finding that Liquidia had established by a preponderance of evidence that claims 1-5, 8, and 9 were unpatentable but had not demonstrated the unpatentability of claims 6 and 7. The Board's unpatentability decision relied, at least in part, on the Winkler Declaration. The Board also denied UTC's motion to exclude the Winkler declaration in its final written decision. J.A. 53-58. The Board rejected Liquidia's arguments of curing via the modified Winkler Declaration but agreed with Liquidia that because UTC deposed Dr. Winkler, UTC suffered no undue prejudice.
UTC timely appealed the Board's decision. We have jurisdiction under 28 U.S.C. § 1295(a)(4)(A). DISCUSSION
UTC raises two issues on appeal. First, UTC argues that the Board erred in denying UTC's motion to exclude the Winkler Declaration. Second, UTC argues that the Board erred in determining that the challenged claims are unpatentable. We address each issue in turn.
Starting with the Board's denial of UTC's motion to exclude the Winkler Declaration, we hold the Board complied with the Administrative Procedure Act.
We review Board decisions for compliance with the Administrative Procedure Act (APA) and set aside "actions of the Board that are arbitrary, capricious, an abuse of discretion, or otherwise not in accordance with law." In re Sullivan, 362 F.3d 1324, 1326 (Fed. Cir. 2004); 5 U.S.C § 706. More specifically, we review the Board's procedural or administrative decisions for an abuse of discretion. Netflix, Inc. v. DivX, LLC, 80 F.4th 1352, 1358 (Fed. Cir. 2023); see 5 U.S.C. § 706(2). An abuse of discretion occurs when a decision "(1) is clearly unreasonable, arbitrary, or fanciful; (2) is based on an erroneous conclusion of law; (3) rests on [a] clearly erroneous fact finding; or (4) involves a record that contains no evidence on which the Board could rationally base its decision." Intelligent Bio-Sys., Inc. v. Illumina Cambridge Ltd., 821 F.3d 1359, 1367 (Fed. Cir. 2016) (quoting Bilstad v. Wakalopulos, 386 F.3d 1116, 1121 (Fed. Cir. 2004)). And of course, when reviewing agency action, we must take account of the rule of harmless error. 5 U.S.C. § 706; Shinseki v. Sanders, 556 U.S. 396, 406 (2009) ().
UTC argues that "[b]y both statute and regulation declarations or affidavits must be sworn or contain indicia of trustworthiness in order to be admissible." Appellant's Br. 14, 19-20. Declarations or affidavits, in UTC's view, "must be accompanied by a warning that false statements are punishable by fine or imprisonment, or include a certification that the statements made therein are true and are offered under penalty of perjury." Id. at 14 (citing 35 U.S.C. §§ 23, 25; 28 U.S.C. § 1746; 37...
Get this document and AI-powered insights with a free trial of vLex and Vincent AI
Get Started for FreeStart Your Free Trial of vLex and Vincent AI, Your Precision-Engineered Legal Assistant
-
Access comprehensive legal content with no limitations across vLex's unparalleled global legal database
-
Build stronger arguments with verified citations and CERT citator that tracks case history and precedential strength
-
Transform your legal research from hours to minutes with Vincent AI's intelligent search and analysis capabilities
-
Elevate your practice by focusing your expertise where it matters most while Vincent handles the heavy lifting
Start Your Free Trial of vLex and Vincent AI, Your Precision-Engineered Legal Assistant
-
Access comprehensive legal content with no limitations across vLex's unparalleled global legal database
-
Build stronger arguments with verified citations and CERT citator that tracks case history and precedential strength
-
Transform your legal research from hours to minutes with Vincent AI's intelligent search and analysis capabilities
-
Elevate your practice by focusing your expertise where it matters most while Vincent handles the heavy lifting
Start Your Free Trial of vLex and Vincent AI, Your Precision-Engineered Legal Assistant
-
Access comprehensive legal content with no limitations across vLex's unparalleled global legal database
-
Build stronger arguments with verified citations and CERT citator that tracks case history and precedential strength
-
Transform your legal research from hours to minutes with Vincent AI's intelligent search and analysis capabilities
-
Elevate your practice by focusing your expertise where it matters most while Vincent handles the heavy lifting
Start Your Free Trial of vLex and Vincent AI, Your Precision-Engineered Legal Assistant
-
Access comprehensive legal content with no limitations across vLex's unparalleled global legal database
-
Build stronger arguments with verified citations and CERT citator that tracks case history and precedential strength
-
Transform your legal research from hours to minutes with Vincent AI's intelligent search and analysis capabilities
-
Elevate your practice by focusing your expertise where it matters most while Vincent handles the heavy lifting
Start Your Free Trial of vLex and Vincent AI, Your Precision-Engineered Legal Assistant
-
Access comprehensive legal content with no limitations across vLex's unparalleled global legal database
-
Build stronger arguments with verified citations and CERT citator that tracks case history and precedential strength
-
Transform your legal research from hours to minutes with Vincent AI's intelligent search and analysis capabilities
-
Elevate your practice by focusing your expertise where it matters most while Vincent handles the heavy lifting